Muroya Daisuke, Arai Shoichiro, Nishida Takamichi, Ishimaru Takahide, Yamazaki Yuta, Goto Youjirou, Nadayoshi Shinya, Kai Yutaro, Masuda Tetsu, Shimokobe Hisaaki, Goto Yuichi, Nagao Yuichi, Wada Yoshito, Torigoe Takayuki, Tomoda Yoshinori, Maruyama Yuji, Imada Hajime, Sou Hironobu, Akagi Yoshito, Hisaka Toru
Department of Surgery, Tobata Kyoritsu Hospital.
Department of Surgery, Kurume University School of Medicine.
Kurume Med J. 2024 Sep 27. doi: 10.2739/kurumemedj.MS7112001.
This study aimed to investigate the efficacy of hyperbaric oxygen therapy (HBOT) in patients presenting with malignant bowel obstruction (MBO) and peritoneal dissemination.
We retrospectively examined whether HBOT affects prognosis following MBO with peritoneal dissemination. This study included 44 patients diagnosed with MBO secondary to peritoneal dissemination at our hospital between January 2013 and December 2022. Among these patients, 30 underwent HBOT. The treatment protocol involved daily HBOT administration, comprising 100% oxygen at 2.5 atmospheres absolute for 60 min.
In a univariate analysis of HBOT and non-HBOT groups, the proportion of patients able to resume eating was significantly higher in the HBOT group. Therefore, the percentage of patients in the non-HBOT group whose MBO did not improve was significantly higher than that in the HBOT group. The percentage of patients undergoing surgery or receiving anticancer treatment did not differ significantly between the groups, whereas overall survival was significantly longer in the HBOT group. Furthermore, when examining inoperable patients, significantly more individuals in the HBOT group could resume eating, and their overall survival was significantly prolonged.
HBOT may increase the spontaneous resolution rate and improve long-term prognoses of patients with MBO secondary to peritoneal dissemination.
本研究旨在探讨高压氧疗法（HBOT）对恶性肠梗阻（MBO）伴腹膜播散患者的疗效。
我们回顾性研究了HBOT对MBO伴腹膜播散患者预后的影响。本研究纳入了2013年1月至2022年12月期间在我院诊断为腹膜播散继发MBO的44例患者。其中，30例接受了HBOT治疗。治疗方案为每日进行HBOT治疗，在2.5绝对大气压下给予100%氧气，持续60分钟。
在对HBOT组和非HBOT组的单因素分析中，HBOT组能够恢复进食的患者比例显著更高。因此，非HBOT组MBO未改善的患者百分比显著高于HBOT组。两组之间接受手术或接受抗癌治疗的患者百分比无显著差异，而HBOT组的总生存期显著更长。此外，在检查无法手术的患者时，HBOT组中能够恢复进食的个体明显更多，且他们的总生存期显著延长。
HBOT可能提高腹膜播散继发MBO患者的自然缓解率并改善其长期预后。
